Supplementary Figure S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Authors:
- Takafumi KoyamaTKTakafumi Koyama
- Toshio ShimizuTSToshio Shimizu
- Yuki KojimaYKYuki Kojima
- Kazuki SudoKSKazuki Sudo
- Hitomi Sumiyoshi OkumaHOHitomi Sumiyoshi Okuma
- Tatsunori ShimoiTSTatsunori Shimoi
- Hitoshi IchikawaHIHitoshi Ichikawa
- Shinji KohsakaSKShinji Kohsaka
- Ryo SadachiRSRyo Sadachi
- Akihiro HirakawaAHAkihiro Hirakawa
- Akihiko YoshidaAYAkihiko Yoshida
- Reiko Makihara AndoRAReiko Makihara Ando
Open Access
- 11 December 2025
- other
- Published by American Association for Cancer Research (AACR)